Companies · Pharmaceuticals

Zogenix Inc

SAN DIEGO · Pharmaceuticals

Diligence memoA one-page analyst read on Zogenix Inc — recommendation, valuation, rhythm, risks.
$131.2M
Total raised · real
6
Rounds
0.4×
Latest step-up
Top 7%
Sector rank · raised
Series C
Latest stage · inferred · Thu Jul 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Zogenix Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.29× the median modeled value of Series C Pharmaceuticals companies in 2010–2012 (12 peers) — value vs value, same stage and era.
Dormant
  • Last raise 16.0 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Zogenix Inc is one of 1610 Pharmaceuticals companies tracked from SAN DIEGO. By capital raised it ranks among the largest (ahead of 94% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeed · 2009-05-15 Raised $3.1M (real) Modeled valuation $118M (est)$3.1M$118MSeed2009Seed · 2009-06-15 Raised $3.1M (real) Modeled valuation $118M (est)$3.1M$118MSeed2009Seed · 2009-07-17 Raised $3.1M (real) Modeled valuation $118M (est)$3.1M$118MSeed2009Series C · 2009-09-22 Raised $71M (real) Modeled valuation $2.5B (est)$71M$2.5BSeries C2009Series B · 2009-09-22 Raised $36M (real) Modeled valuation $1.2B (est)$36M$1.2BSeries B2009Series C · 2010-07-01 Raised $15M (real) Modeled valuation $526M (est)$15M$526MSeries C2010+$3.1M+$3.1M+$71M+$36M+$15MCumulative $131M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.1M · 2009
Seed extension$3.1M · 2009
Seed extension$3.1M · 2009
Series C$71.0M · 2009no Series A / Series B on file
Bridge · Series C-stage$36.0M · 2009smaller follow-on
Series C extension$15.0M · 2010

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$526.4M
Base estimate est.
$48.7M
Conservative case
$1.4B
Upside case
$100.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $117.9M · 2009-05-152009Seed · modeled $117.9M · 2009-06-15Seed · modeled $117.9M · 2009-07-17Series C · modeled $2.5B · 2009-09-22Series B · modeled $1.2B · 2009-09-22Series C · modeled $526.4M · 2010-07-012010
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
16.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
3 mo
Avg between rounds
$116.3M/yr
Capital velocity
17.1 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 16× above median
This company$131.2M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.3× of median
This company$15.0M
Sector median$46.7M
Modeled value — vs sector median (estimate, all stages) 6.9× above median
This company$526.4M
Sector median$76.1M

Raised more than 94% of sector peers (real $). Modeled value above 81% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 12.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Acadia Pharmaceuticals Inc · Series C Raised $107.5M · modeled $3.0B (est)Agios Pharmaceuticals Inc · Series C Raised $86.8M · modeled $2.7B (est)Merrimack Pharmaceuticals Inc · Series C Raised $77.0M · modeled $2.7B (est)PCAS Patient Care Automation Services Inc. · Series C Raised $77.0M · modeled $2.5B (est)China Medicine Corp · Series C Raised $69.6M · modeled $2.4B (est)Brickell Bay Acquisition Corp. · Series C Raised $52.4M · modeled $1.8B (est)Achillion Pharmaceuticals Inc · Series C Raised $50.1M · modeled $1.8B (est)Aragon Pharmaceuticals, Inc. · Series C Raised $141.5M · modeled $1.8B (est)Global Pharm Holdings Group, Inc. · Series C Raised $66.0M · modeled $350.9M (est)Portola Pharmaceuticals Inc · Series C Raised $158.1M · modeled $315.8M (est)Aveo Pharmaceuticals Inc · Series C Raised $98.2M · modeled $263.2M (est)Zogenix Inc (this company) Raised $131.2M · modeled $526.4M (est)Zogenix Inc
CompanyStageRaised · realValue · estvs peer med.
Acadia Pharmaceuticals IncSeries C$107.5M$3.0B1.69×
Agios Pharmaceuticals IncSeries C$86.8M$2.7B1.52×
Merrimack Pharmaceuticals IncSeries C$77.0M$2.7B1.50×
PCAS Patient Care Automation Services Inc.Series C$77.0M$2.5B1.37×
China Medicine CorpSeries C$69.6M$2.4B1.36×
Brickell Bay Acquisition Corp.Series C$52.4M$1.8B1.02×
Achillion Pharmaceuticals IncSeries C$50.1M$1.8B0.98×
Aragon Pharmaceuticals, Inc.Series C$141.5M$1.8B0.98×
Zogenix Inc this companySeries C$131.2M$526.4M0.29×
Global Pharm Holdings Group, Inc.Series C$66.0M$350.9M0.20×
Portola Pharmaceuticals IncSeries C$158.1M$315.8M0.18×
Aveo Pharmaceuticals IncSeries C$98.2M$263.2M0.15×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.1M2009-05-15$15.5M$117.9M90%
Seed$3.1M2009-06-15$15.5M$117.9M90%
Seed$3.1M2009-07-17$15.5M$117.9M90%
Series C$71.0M2009-09-22$473.1M$2.5B90%
Series B$36.0M2009-09-22$199.8M$1.2B90%
Series C$15.0M2010-07-01$100.0M$526.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.1M2009-05-15
    • First recorded raise — entered as Seed.
  2. Seed$3.1M2009-06-15
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
  3. Seed$3.1M2009-07-17
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
  4. Series C$71.0M2009-09-22
    • Came back fast: 2 mo vs the ~13 mo sector norm.
    • Round 22.9× larger than the prior — scaling up.
  5. Series B$36.0M2009-09-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
  6. Series C$15.0M2010-07-01
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 2.4× smaller than the prior — bridge or down round.
Intelligence
2010 ~Q3
Modeled next raise · ~3mo cadence
$15.0M
Modeled next size est.range $15.0M$24.0M
0.4×
Last step-up
$116.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Cam L. Garner10 other2009-06
James C. Blair7 other2009-05
Louis C. Bock6 other2009-05
Alex Zisson2 other2009-05
Arda M. Minocherhomjee2 other2010-07
Erle T. Mast2 other2009-05
Kurt C. Wheeler2 other2009-05
Ann D. Rhoads1 other2010-07
Arda M. Minocherhomjee, Ph.D.1 other2009-09
Cam Garner1 other2009-05
David W. Nassif1 other2009-05
Ken M. Haas1 other2010-07
Ken T. Haas1 other2009-09
Roger L. Hawley1 other2009-05
Alex C. Zisson2009-09
Cynthia Y. Robinson2009-05
J.D. Haldeman2009-05
J.D. Y. Haldeman2009-09
Stephen J. Farr2009-05
Registry & provenance

Zogenix Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1375151
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Clovis Oncology, Inc.PharmaceuticalsSeries D+$358.3M$6.8Bnetwork2 shared operators · same sector
Zavante Therapeutics, Inc.PharmaceuticalsSeries C$60.2M$1.6Bnetwork1 shared operator · same sector · same stage
Somaxon Pharmaceuticals, Inc.PharmaceuticalsSeries A$6.0M$185.8Mnetwork2 shared operators · same sector
Axial Biotherapeutics, Inc.PharmaceuticalsSeries B$109.8M$107.8Mnetwork1 shared operator · same sector
Arthrosi Therapeutics, Inc.PharmaceuticalsSeries C$132.9M$385.2Msame sector · same stage
Aeovian Pharmaceuticals, Inc.PharmaceuticalsSeries C$125.0M$297.5Msame sector · same stage
Tenax Therapeutics, Inc.PharmaceuticalsSeries C$138.4M$840.7Msame sector · same stage
Mirum Pharmaceuticals, Inc.PharmaceuticalsSeries C$138.5M$347.9Msame sector · same stage
Frequently asked
How much funding has Zogenix Inc raised?
Zogenix Inc has raised approximately $131.2M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Zogenix Inc's estimated valuation?
Provath's modeled valuation for Zogenix Inc is approximately $526.4M (modeled range $48.7M–$1.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Zogenix Inc at?
Zogenix Inc's latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Jul 01.
What does Zogenix Inc do and where is it based?
Zogenix Inc operates in the Pharmaceuticals sector, based in SAN DIEGO.
Explore related

See where Zogenix Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Zogenix Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.